| 1/5 | US=16-A / Estatística Singh MS, Michael M. Role of xenobiotic metabolic enzymes in cancer epidemiology. In: Verma M. Cancer epidemiology. New York: Humana Press, 2009. p. 243-64. (Methods in Molecular Biology, 472) ISBN 978-1-60327-491-3. XENOBIOTICOS ENZIMAS. CANCRO; XENOBIOTICOS; EPIDEMIOLOGIA DO CANCRO; P450; ALCOOL DESIDROGENASE; ALDEIDO DESIDROGENASE; GLUTATIONA-S-TRANSFERASE; SULFATASE; RISCO DE CANCER |
| 2/5 | US=16 / Urologia Nelson WG, Yegnasubramanian S, Bastian PJ, Nakayama M, De Marzo AM. Genetics: somatic DNA methylation changes and prostatic carcinogenesis. In: Chung LWK, Isaacs WB, Simons JW. Prostate cancer: biology, genetics, and the new therapeutics. 2ª ed. New Jersey: Humana Press, 2007. p. 301-15. (Contemporary Cancer Research) ISBN 978-1-58829-696-2. CANCER DE PROSTATA; GENETICA; METILACAO DE DNA SOMATICAS; CARCINOGENESE PROSTATICA; ESTRUTURA DA CROMATINA; METILACAO DO DNA; DNA METILTRANSFERASE; EPIGENETICA; GLUTATIONA-S-TRANSFERASE |
| 3/5 | US=61 / Câncer Findlay VJ, Townsed DM, Tew KD. Biochemical resistance: glutathione S-transferases in drug resistance. In: Teicher BA. Cancer drug resistance. New Jersey: Humana Press, 2006. p. 213-21. (Cancer Drug Discovery and Development) ISBN 978-1-58829-530-1. GLUTATIONA; GLUTATIONA-S-TRANSFERASE; RESISTENCIA AS DROGAS; CANCER; MAPK; CAMINHO |
| 4/5 | US=61 / Câncer Hazlehurst LA, Dalton WS. Biochemical resistance: de novo and acquired resistance to antitumor alkylating agents. In: Teicher BA. Cancer drug resistance. New Jersey: Humana Press, 2006. p. 377-89. (Cancer Drug Discovery and Development) ISBN 978-1-58829-530-1. AGENTES ALQUILANTES ANTITUMORAIS; DE NOVO A RESISTENCIA; RESISTENCIA ADQUIRIDA; GLUTATIONA; GLUTATIONA-S-TRANSFERASE; FANCONI ANEMIA/BRCA1 CAMINHO |
| 5/5 | US=22-C / Câncer Travis LB, Bhatia S, Allan JM, Oeffinger KC, Ng A. Segundo câncer. In: DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. 10 ed. Philadelphia: Wolters Kluwer, 2015. p. 2047-2067. ISBN 978-1-45119294-0. CARCINOGENICIDADE DE MODALIDADES DE TRATAMENTO INDIVIDUAIS. RADIOTERAPIA; CARCINOGENICIDADE DE MODALIDADES DE TRATAMENTO INDIVIDUAIS. QUIMIOTERAPIA; SUSCEPTIBILIDADE GENETICA SEGUNDO CANCER PRIMARIO; ENZIMAS DE ATIVACAO / VIAS DE DESINTOXICACAO DO METABOLISMO DE DROGAS; ENZIMAS DO CITOCROMO P450; GLUTATIONA-S-TRANSFERASE; RISCO DE SEGUNDA NEOPLASIA EM PACIENTES COM CANCERES PRIMARIOS SELECIONADOS; NEOPLASIAS PEDIATRICAS; CANCER DE MAMA SECUNDARIO; CANCER DE TIROIDE SECUNDARIO; OSTEOSSARCOMA SECUNDARIO; TUMOR DO SISTEMA NERVOSO CENTRAL SECUNDARIO; MELANOMA SECUNDARIO; OUTROS CARCINOMAS SECUNDARIOS |